Relationship between Systolic Ejection Time and Inflammation in End-Stage Heart Failure

被引:0
|
作者
Gutovitz, Joel [1 ]
Kutcher, Jonathan [1 ]
Cherney, David Z. [2 ]
Schiller, Yael [1 ]
Gabizon, Itzhak [3 ]
Keshet, Eran [4 ]
Rimon, Jordan [4 ]
Koren, David [5 ]
Rao, Vivek [6 ]
Grosman-Rimon, Liza [7 ]
机构
[1] Technion, Ruth & Bruce Rappaport Fac Med, Haifa, Israel
[2] Univ Toronto, Toronto Gen Hosp, Div Nephrol, Toronto, ON, Canada
[3] Ben Gurion Univ Negev, Fac Hlth Sci, Soroka Med Ctr, Dept Cardiol, Beer Sheva, Israel
[4] York Univ, Fac Hlth, Toronto, ON, Canada
[5] Sheba Med Ctr, Dept Cardiac Surg, Tel Hashomer, Israel
[6] Univ Hlth Network, Toronto Gen Hosp, Peter Munk Cardiac Ctr, Toronto, ON, Canada
[7] Acad Coll Levinsky Wingate, Wingate Inst, IL-6937808 Netanya, Israel
关键词
end-stage heart failure; inflammation; systolic ejection time; CARDIAC MYOSIN ACTIVATOR; CHEMOKINES; RECEPTORS;
D O I
10.14423/SMJ.0000000000001801
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
ObjectivesSystolic ejection time (SET) and systemic inflammation are two essential indicators of heart failure (HF) progression. We aimed to evaluate the associations between SET and inflammatory mediators in end-stage HF. MethodsParticipants included 16 patients with end-stage HF recruited from the Heart Failure Clinic at Toronto General Hospital and 16 healthy individuals free of any known cardiovascular disease. SET, end systolic pressure, and levels of inflammatory mediators were documented for each patient, and a Spearman rank correlation coefficient was performed to examine differences between patients with end-stage HF and healthy controls. ResultsThe mean SET in patients with HF was shorter than in the healthy controls (283.5 +/- 34.3 ms vs 330.1 +/- 19.0 ms, P < 0.001). C-reactive protein (P = 0.001), macrophage inflammatory protein-1 beta (P = 0.041), macrophage-derived chemokine (P = 0.007), and cyclic guanosine monophosphate (P < 0.001) levels were negatively correlated with SET. The levels of other inflammatory mediators-granulocyte-stimulating factor, granulocyte-macrophage colony-stimulating factor, interleukin-8, macrophage inflammatory protein-1, macrophage inflammatory protein-1 alpha, and tumor necrosis factor alpha-were not significantly correlated with SET. ConclusionsWe found that SET was significantly lower in patients with end-stage HF compared with healthy controls and that reduced SET correlated with increased levels of several inflammatory mediators in patients with HF. By better understanding the relationship between SET and inflammation in HF, a more thorough evaluation could lead to improved risk stratification among patients with HF. Future work should investigate the roles of SET and inflammation in HF.
引用
收藏
页码:167 / 170
页数:4
相关论文
共 50 条
  • [1] MitraClip® therapy in patients with end-stage systolic heart failure
    Franzen, Olaf
    van der Heyden, Jan
    Baldus, Stephan
    Schlueter, Michael
    Schillinger, Wolfgang
    Butter, Christian
    Hoffmann, Rainer
    Corti, Roberto
    Pedrazzini, Giovanni
    Swaans, Martin J.
    Neuss, Michael
    Rudolph, Volker
    Suerder, Daniel
    Gruenenfelder, Juerg
    Eulenburg, Christine
    Reichenspurner, Hermann
    Meinertz, Thomas
    Auricchio, Angelo
    EUROPEAN JOURNAL OF HEART FAILURE, 2011, 13 (05) : 569 - 576
  • [2] MitraClip implantation in patients with end-stage systolic heart failure
    Fiorelli, F.
    Giannini, C.
    De Carlo, M.
    Petronio, A. S.
    Tamburino, C.
    Capodanno, D.
    Ettori, F.
    Fiorina, C.
    Bedogni, F.
    Brambilla, N.
    EUROPEAN HEART JOURNAL, 2014, 35 : 694 - 694
  • [3] Association between systolic ejection time and outcomes in heart failure by ejection fraction
    Patel, Priyesh A.
    Ambrosy, Andrew P.
    Phelan, Matthew
    Alenezi, Fawaz
    Chiswell, Karen
    Van Dyke, Melissa K.
    Tomfohr, Jennifer
    Honarpour, Narimon
    Velazquez, Eric J.
    EUROPEAN JOURNAL OF HEART FAILURE, 2020, 22 (07) : 1174 - 1182
  • [4] Incidence and Predictors of End-Stage Renal Disease in Outpatients With Systolic Heart Failure
    Bosselmann, Helle
    Gislason, Gunnar
    Gustafsson, Finn
    Hildebrandt, Per R.
    Videbaek, Lars
    Kober, Lars
    Torp-Pedersen, Christian
    Tonder, Niels
    Rossing, Kasper
    Christensen, Stefan
    Kamper, Anne-Lise
    Heaf, James
    Schou, Morten
    CIRCULATION-HEART FAILURE, 2013, 6 (06) : 1124 - 1131
  • [5] PREDICTORS OF END-STAGE RENAL DISEASE IN OUTPATIENTS WITH STABLE SYSTOLIC HEART FAILURE
    Bosselmann, Helle Skovmand
    Gislason, Gunnar H.
    Hildebrandt, Per
    Gustafsson, Finn
    Videbaek, Lars
    Koeber, Lars
    Torp-Pedersen, Christian
    Toender, Niels
    Rossing, Kasper
    Christensen, Stefan
    Kamper, Anne-Lise
    Heaf, James
    Schou, Morten
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2013, 61 (10) : E2118 - E2118
  • [6] ICDs in end-stage heart failure
    Pettit, Stephen J.
    Browne, Susan
    Hogg, Karen J.
    Connelly, Derek T.
    Gardner, Roy S.
    May, Carl R.
    Macleod, Una
    Mair, Frances S.
    BMJ SUPPORTIVE & PALLIATIVE CARE, 2012, 2 (02) : 94 - 97
  • [7] Levosimendan in End-Stage Heart Failure
    Yeo, Poh Shuan Daniel
    JACC-HEART FAILURE, 2013, 1 (04) : 365 - 365
  • [8] Dilemmas in end-stage heart failure
    Chen-Scarabelli, Carol
    Saravolatz, Louis
    Hirsh, Benjamin
    Agrawal, Pratik
    Scarabelli, Tiziano M.
    JOURNAL OF GERIATRIC CARDIOLOGY, 2015, 12 (01) : 57 - 65
  • [9] Management of end-stage heart failure
    Moulopoulos, SD
    INTERNATIONAL JOURNAL OF ARTIFICIAL ORGANS, 1996, 19 (06): : 327 - 328
  • [10] Midodrine in end-stage heart failure
    Gonzalez-Cordero, Ariel
    Ortiz-Troche, Stephanie
    Nieves-Rivera, Juan
    Mesa-Pabon, Marcel
    Franqui-Rivera, Hilton
    BMJ SUPPORTIVE & PALLIATIVE CARE, 2023, 13 (E1) : E86 - E87